Your browser doesn't support javascript.
loading
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak, Mareike; Tucker, Elizabeth; Dorel, Mathurin; Winkler, Annika; McGearey, Aleixandria; Rodriguez-Fos, Elias; da Costa, Barbara Martins; Barker, Karen; Fyle, Elicia; Calton, Elizabeth; Eising, Selma; Ober, Kim; Hughes, Deborah; Koutroumanidou, Eleni; Carter, Paul; Stankunaite, Reda; Proszek, Paula; Jain, Neha; Rosswog, Carolina; Dorado-Garcia, Heathcliff; Molenaar, Jan Jasper; Hubank, Mike; Barone, Giuseppe; Anderson, John; Lang, Peter; Deubzer, Hedwig Elisabeth; Künkele, Annette; Fischer, Matthias; Eggert, Angelika; Kloft, Charlotte; Henssen, Anton George; Boettcher, Michael; Hertwig, Falk; Blüthgen, Nils; Chesler, Louis; Schulte, Johannes Hubertus.
Afiliación
  • Berlak M; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Tucker E; Berlin School of Integrative Oncology (BSIO), Augustenburger Platz 1, 13353, Berlin, Germany.
  • Dorel M; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstr.31, 12169, Berlin, Germany.
  • Winkler A; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • McGearey A; Otto Warburg Laboratory Gene Regulation and Systems Biology of Cancer, Max Planck Institute for Molecular Genetics, Berlin, Germany.
  • Rodriguez-Fos E; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
  • da Costa BM; IRI Life Sciences, Humboldt University Berlin, 10115, Berlin, Germany.
  • Barker K; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Fyle E; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Calton E; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Eising S; Experimental and Clinical Research Center (ECRC) of the Charité and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125, Berlin, Germany.
  • Ober K; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Hughes D; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Koutroumanidou E; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Carter P; Paediatric Solid Tumour Biology and Therapeutics Team, Clinical Division and Cancer Therapeutics Division, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Stankunaite R; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Proszek P; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Jain N; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Rosswog C; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Dorado-Garcia H; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Molenaar JJ; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Hubank M; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Barone G; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Anderson J; Department of Experimental Pediatric Oncology, Center for Molecular Medicine Cologne, 50931, Cologne, Germany.
  • Lang P; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Deubzer HE; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Künkele A; Department of pharmaceutical sciences, Utrecht University, Utrecht, The Netherlands.
  • Fischer M; Molecular Diagnostics Department, The Institute of Cancer Research and Clinical Genomics, The Royal Marsden NHS Foundation, London, UK.
  • Eggert A; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Kloft C; Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK.
  • Henssen AG; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Boettcher M; Department of Pediatric Hematology and Oncology, University Hospital, Tübingen, Germany.
  • Hertwig F; Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Blüthgen N; Experimental and Clinical Research Center (ECRC) of the Charité and Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, 13125, Berlin, Germany.
  • Chesler L; German Cancer Consortium (DKTK), Berlin, Germany.
  • Schulte JH; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Mol Cancer ; 21(1): 126, 2022 06 10.
Article en En | MEDLINE | ID: mdl-35689207
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Child / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania